Navigation Links
King and Pain Therapeutics Announce REMOXY(R) NDA Update
Date:7/7/2009

s and acquisitions, of novel branded prescription pharmaceutical products that complement the Company's focus in specialty-driven markets, particularly neuroscience, hospital care. King's wholly-owned subsidiary, Alpharma, Inc., is also a leader in the development, registration, manufacturing and marketing of pharmaceutical products for food producing animals.

About Pain Therapeutics, Inc.

Pain Therapeutics, Inc. is a biopharmaceutical company that develops novel drugs. In addition to REMOXY, the Company has three drug candidates in clinical programs, including a novel radio-labeled monoclonal antibody to treat metastatic melanoma, as well as PTI-202 and PTI-721. Pain Therapeutics is also working on a new treatment for patients with hemophilia. For more information, please visit www.paintrials.com.

Forward Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Pain Therapeutics, Inc. and King Pharmaceuticals, Inc. disclaim any intent or obligation to update these forward-looking statements, and claim the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, any statements relating to the resubmission of the NDA for REMOXY(R), and the timing and content of any such resubmission; the need to generate stability data or any other information in connection with the resubmission; the Companies' plans to develop and commercialize REMOXY(R); the Companies' plans to work with the FDA in connection with the Complete Response Letter; and the potential approval of the NDA for REMOXY(R). Such statements are based on management's current expectations, but actual results may differ materially due to various factors. Such statements in
'/>"/>

SOURCE King Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics Added to Russell 3000(R), Russell 2000(R) and Russell Global(R) Indexes
2. Yaupon Therapeutics Completes Patient Enrollment for Pivotal Phase 2 Study of Clearazide for Treatment of Cutaneous T-cell Lymphoma
3. Horizon Therapeutics Names Dr. Jeffrey W. Sherman Executive Vice President and Chief Medical Officer
4. PTC Therapeutics Receives $2.6 Million in Government Grants
5. Cell Therapeutics on Preliminary List of Additions to Russell 3000(R) Index and Russell Global(R) Index
6. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer
7. CSL Limited and Talecris Biotherapeutics Agree to Terminate Merger Agreement
8. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
9. Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions
10. Tobira Therapeutics Inc. Announces Key Addition to Scientific Advisory Board
11. PeriCor Therapeutics Reports Positive Preclinical Results of GP531 at the European Heart Failure Congress in Nice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Calif. , Feb. 26, 2015   Regulus ... biopharmaceutical company leading the discovery and development of innovative ... Xanthopoulos , Ph.D., President and Chief Executive Officer of ... and Company 35 th Annual Healthcare Conference on ... conference is being held at the Boston Marriott Copley ...
(Date:2/26/2015)... Woodbridge, NJ (PRWEB) February 26, 2015 ... and its affiliated companies, Wilentz, Goldman & ... in a trade secrets lawsuit against Genewiz Inc. in ... illegally obtained and utilized GenScript’s trade secrets, and that ... The court entered an order denying motions for ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 The ... -12, at the Ernest N. Morial Convention Center ... (count as of February 19, 2015) displaying products ... industrial, academic, and government labs. The Exposition will ... but not limited to, analytical chemistry; drug discovery; ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 According to ... “Agricultural Biotechnology Market For Transgenic Crops (Corn, Soybean, Cotton ... Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 ... USD 15,300 million in 2012 and is expected to ... CAGR of 9.5% from 2013 to 2019. , ...
Breaking Biology Technology:Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Pittcon 2015 Announces Exposition Highlights 2Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 2Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 3
... , STAMFORD, Conn., Sept. ... announced that it has established a Strategic Advisory Board ... within the healthcare industry. The Board will be comprised ... management experience. Each member is expected to supplement Cowen ...
... Attorneys ... ... Rudnick, an international law firm, today announced that a veteran Intellectual Property ("IP") team ... years of combined experience, the team includes Partners Thomas C. Meyers and Robert J. ...
... Kensey Nash Corporation (Nasdaq: KNSY ) is scheduled ... the Grand Hyatt New York in New York City on Monday, ... Kensey Nash,s President & CEO, will deliver the Company,s presentation, beginning ... of the Kensey Nash presentation at the UBS Global Life Sciences ...
Cached Biology Technology:Cowen Healthcare Royalty Partners Establishes Strategic Advisory Board 2Cowen Healthcare Royalty Partners Establishes Strategic Advisory Board 3Cowen Healthcare Royalty Partners Establishes Strategic Advisory Board 4Veteran Intellectual Property Team Joins Brown Rudnick 2
(Date:2/5/2015)... IRVINE, Calif. , Jan. 27, 2015 ... trusted provider of globally deployed, innovative test ... today announced the delivery of its ... Martin Space Systems Company (LMSSC). GENASYS is ... the demands of mission-critical applications that require ...
(Date:2/5/2015)... Research and Markets ( http://www.researchandmarkets.com/research/6lngtl/global_biometrics ... "Global Biometrics Market (2014-2020): Market Forecast By Technologies, ... to their offering. , In ... is anticipated to overtake North America ... spending towards IT security, government biometric based projects ...
(Date:1/22/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has ... Market Overview" report to their offering. , ... that an individual is who she/he is claiming to be, ... a person,s unique physical characteristics, such as fingerprint, hand or ...
Breaking Biology News(10 mins):Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3
... the difficulty of capturing a clear picture of a ... molecules, however, sometimes the motion is exactly what scientists ... pathological protein mis-folding and assembly that seem to underlie ... disease. , Now, chemists at the ...
... to treat Helicobacter pylori (H. pylori) infection, a ... in around 25 percent of cases. A new ... finds that adding a bovine protein called lactoferrin ... results, with fewer of the side effects associated ...
... organisms are at risk from seafloor mining scheduled ... study led by a University of Toronto Mississauga ... near "black smokers"—undersea hydrothermal vent systems that spew ... and support sulphur-loving bacteria and bizarre worm and ...
Cached Biology News:Decoding protein structures helps illuminate cause of diabetes 2Study warns deep-sea mining may pose serious threat to fragile marine ecosystems 2Study warns deep-sea mining may pose serious threat to fragile marine ecosystems 3
AVOID FREEZE/THAW CYCLES. Recognizes the UCP-2 protein....
... bridges the gap between the 500 l ... combines the speed of the classic Vivaspin ... area for superior recoveries from very dilute ... PES, Cellulose Triacetate membranes, Vivaspin 2 offers ...
... VAMP-2 (Vesicle-Associated Membrane Protein 2, ... not share homology with any ... It is expected that the ... human, Macaca multata and bovine ...
... Transporter 2 (VMAT2). An antibody made to ... band at ~55 kDa in postnuclear supernatants ... in wild type cells (2). Some additional ... were also detected and remain unaffected by ...
Biology Products: